Home » Blog » ASCO and 300+ Advocacy Groups Urge Withdrawal of Medicare Part B Payment Model Proposal

ASCO and 300+ Advocacy Groups Urge Withdrawal of Medicare Part B Payment Model Proposal

IP Blog | Dave Melin | March 27, 2016

BioBlog Weekly oncologyThis week in healthcare: ASCO and over 300 healthcare organizations and patient groups request that Congress intervene and request the withdrawal of CMS’s proposed Medicare Part B Payment Model.

ASCO, More than 300 Advocacy Groups Request Withdrawal of Medicare Part B Drug Proposal

After CMS’s release of a proposed Medicare Part B drug reform policy, ASCO and over 300 other advocacy organizations submitted a letter to Congress “urging lawmakers to ask the Centers for Medicare & Medicaid Services (CMS) to withdraw its proposed Medicare Part B Payment Model.”

ASCO’s Incoming President-Elect Charts His Course for 2017

This ASCO Post article takes a look at Bruce E. Johnson, who was recently elected as the incoming ASCO President for 2017-2018.

Clifford A. Hudis, MD, FACP, Named ASCO’s Next CEO

As current ASCO CEO Allen Lichter prepares to step down this summer, ASCO has announced former ASCO president and breast cancer expert Clifford A. Hudis will succeed Lichter as CEO beginning in June.

Why a Patient-Centered Approach to Clinical Pathways Must Include Palliative Care

In this article, Dr. Geoffrey Dunn talks about the origins of the palliative care movement and why “in order to give patients the highest quality of life, palliative care is often a better option than treatment for patients with poor prognoses.”

Greater Alignment Among Oncology Clinical Pathways is Needed

In the world of clinical pathways, “implementation of cost-containing strategies has differential impact on the various stakeholders, and there is understandable tension between payers and providers with respect to how to balance accomplishing these aims.” So this article takes a look at how the differing camps can work together to make oncology clinical pathways work.

Impact of Government Cost Controls on Treatment Selection for Clinical Pathways

This report takes a look at “the different cost control levers the government could use to affect drug pricing and/or utilization, which, in turn, can have an impact on the treatments selected for and placed within clinical pathways.”

Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.

Topics in this Post:

Leave a Comment

Your email address will not be published. Required fields are marked *